Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Q1 2017 Earnings Presentation
21 slides from Orion Oyj Class A's earnings presentation, Apr 26, 2017
Slide 1: Orion Interim Report 1/1/2017–31/3/2017
Orion Interim Report 1/1/2017–31/3/2017
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Orion's centenary year started well
Orion’s centenary year started well ● Net sales and operating profit increased 3M 2016 3M 2017 ● Operating profit boosted by higher milestone payments than in previous year 279 262 ● Christer Nordstedt became Senior Vice President for Research and Development in February ● Marketing authorisation ap
Slide 4: Geographical breakdown of net sales
Geographical breakdown of net sales By market area Orion’s sales network 18% Finland 29% Scandinavia 7% Other Europe North America ROW 16% 30% 4 26 April 2017 Orion Financial Review 1/1/2017–31/3/2017 © Orion Corporation
Slide 5: Breakdown of net sales by business division
Breakdown of net sales by business division 3M 3M 2017 2016 Change Proprietary Products 4% 5% Specialty Products 122 123 -1% 5% Specialty Products Proprietary Products 98 88 +12% 7% 35% Animal Health Animal Health 19 18 +5% Fermion Fermion 16 11 +47% Contract Manufacturing Contract Manufacturing & o
Slide 6: Pharmaceuticals business
Pharmaceuticals business 6 26 April 2017 Orion Financial Review 1/1/2017–31/3/2017 © Orion Corporation
Slide 7: Best-selling pharmaceuticals 3M 2017
Best-selling pharmaceuticals 3M 2017 Net sales Change vs. Product Indication EUR million 3M 2016 1. Parkinson’s disease 30 -7% 2. Asthma, COPD 18 +15% 3. Intensive care sedative 17 +18% 4. Acute decompensated heart failure 15 +12% Rheumatoid arthritis, inflammatory 5. bowel diseases 11 -6% 6. Animal
Slide 8: Proprietary Products
Proprietary Products Breakdown of net sales ● As anticipated, sales of Stalevo, Comtess and Comtan continued to decline Stalevo, Comtess ● Easyhaler product family, Dexdor and Simdax 11% & Comtan grew strongly Easyhaler 7% 31% ● Sales of Precedex grew by 79% mainly due to Dexdor deliveries of the ph
Slide 9: Parkinson's drugs
Parkinson’s drugs 60 Sales of Orion’s branded Parkinson drugs 50 by market area MAT12/2016* 3% EUR million 40 30 20 27% Europe 10 42% Japan 0 ROW Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1 USA 2013 2014 2015 2016 17 28% Orion sales Deliveries to Novartis *Source: IMS Health sales statistics MAT12/2016 9 26 Ap
Slide 10: Easyhaler product family
Easyhaler product family ● Total Easyhaler product family sales grew by 15% 20 18 ● Bufomix Easyhaler sales grew by 38% 16 ● Marketing authorisation application for Easyhaler EUR million 14 12 salmeterol-fluticasone combined formulation 10 submitted in Europe 8 6 4 2 0 Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4
Slide 11: Dexdor intensive care sedative
Dexdor intensive care sedative European sedative market MAT12/2016* Dexdor sales Total market value EUR 523 million (-0.5%) 18 16 14 13% EUR million 12 10 9% 8 66% 12% 6 4 2 0 Propofol EUR 342 million (-1%) Midazolam EUR 69 million (-9%) Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1 Dexmedetomidine EUR 48 millio
Slide 12: Specialty Products
Specialty Products Net sales in key markets 3M 2017 Breakdown of net sales vs. 3M EUR million 2016 14% Finland Finland 72 +3% Scandinavia 20 -8% 11% Scandinavia Eastern Europe and Russia 13 +9% • In Finland changes to reference pricing system for 16% 59% Eastern Europe & substitutable prescription d
Slide 13: Orion strong in home market Finland
Orion strong in home market Finland Finland’s biggest pharmaceutical companies 3M 2017 Finnish human pharmaceuticals market 3M 2017 80 ● Wholesale EUR 546 million 72 ● Growth of total market +1% 60 EUR million ● Orion's market share 13% ● Orion's growth +4% 40 31 31 – Orion's growth was mainly due t
Slide 14: Key clinical pharmaceutical development projects 1/2
Key clinical pharmaceutical development projects 1/2 Project Indication PHASE Registration Bioequivalence Easyhaler® salmeterol-fluticasone Asthma, COPD Registration study Darolutamide (ODM-201) 1) Prostate cancer (nmCRPC) I II III Darolutamide (ODM-201) 1) Prostate cancer (mHSPC) I II III Levosimen
Slide 15: Key clinical pharmaceutical development projects 2/2
Key clinical pharmaceutical development projects 2/2 Project Indication PHASE Registration ODM-109 (oral levosimendan) ALS I II ORM-12741 (alpha-2c adrenoceptor antagonist) 3) Alzheimer’s disease I IIa ODM-104 (more effective COMT inhibitor) Parkinson’s disease I II ODM-203 (targeted FGFR+VEGFR inhi
Slide 16: Diagnostics business
Diagnostics business 16 26 April 2017 Orion Financial Review 1/1/2017–31/3/2017 © Orion Corporation
Slide 17: Orion Diagnostica
Orion Diagnostica 3M 2016 3M 2017 ● QuikRead® tests remained the main product 14 14 ● Operating profit increased thanks to growth in sales with good margins, among other things 2.6 3.5 Net sales, Operating profit, EUR million EUR million +7% +32% 17 26 April 2017 Orion Financial Review 1/1/2017–31/3
Slide 18: Outlook for 2017
Outlook for 2017 Net sales are estimated to be at similar level to 2016 Net sales (net sales were EUR 1,074 million in 2016). Operating profit excluding material capital gains is estimated to be at least EUR Operating profit 280 million (operating profit excluding capital gains was EUR 293 million i
Slide 19: Orion Calendar
Orion Calendar Capital Markets Day for analysts, institutional Thursday 18 May 2017 investors and media in Helsinki Half-Year Financial Report January–June 2017 Wednesday 19 July 2017 Interim Report January–September 2017 Thursday 26 October 2017 19 26 April 2017 Orion Financial Review 1/1/2017–31/3
Slide 20: Capital Markets Day 18 May 2017 Helsinki
Capital Markets Day 18 May 2017 Helsinki www.orion.fi/en/cmd2017
Slide 21: Building well-being. Together.
Building well-being. Together.